U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185282) titled 'A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis' on Sept. 12.
Brief Summary: This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.
Study Start Date: June 10, 2023
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: MH004 Ointment
MH004 1% ointment applied topically ...